Stay updated with breaking news from Michael Benatar. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Following implementation of low-dose rituximab as standard of care for muscle-specific kinase–positive myasthenia gravis (MuSK-MG), a hospital evaluated the treatment’s efficacy over a 2-year period.
The FDA’s recent accelerated approval of a drug to treat a genetic variant of ALS is not only helping patients diagnosed with the disease, it could be used to slow or even stop the progression before symptoms first appear.
Cartesian Therapeutics, a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.
- New Clinical Data on ARO-RAGE Show Continued Dose Response with Single Inhaled Dose of 184 mg Achieving Mean Knockdown of 90% and Max of 95% - Adipose Delivery Platform Achieved Single Dose... | June 1, 2023
- Event to include presentations on cardiometabolic, pulmonary, and newly announced central nervous system pipeline programs ... | April 12, 2023